Safety and Efficacy of Sitravatinib plus Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

被引：0

作者：

Khan, N. ^{[1
]}

Newman, J. ^{[2
]}

Rahman, H. ^{[3
]}

Lee, C-S. ^{[2
,4
]}

Kohn, N. ^{[3
]}

Seetharamu, N. ^{[2
]}

机构：

[1] Northwell Hlth, Manhasset, NY USA

[2] Northwell Hlth, Canc Inst, Lake Success, NY USA

[3] Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY USA

[4] St Johns Univ, Queens, NF, Canada

来源：

关键词：

sitravatinib; tislelizumab; NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.01-07

引用

页码：S373 / S374

页数：2